Form 483

Columbia Cosmetics Manufacturing, Inc. Form 483, 2025-04-14

FDA issued a Form 483 to Columbia Cosmetics Manufacturing, Inc. on 2025-04-14 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

Columbia Cosmetics Manufacturing, Inc. · San Leandro, United States · Issued April 14, 2025

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

14 Apr 2025
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Anney Lin, Nathan E Hellman

14 Apr 2025
21 CFR 211.165(f)

Failing drug products not rejected

Cited by Anney Lin, Nathan E Hellman

14 Apr 2025
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Anney Lin, Nathan E Hellman

14 Apr 2025
21 CFR 211.67(b)(3)

Cleaning SOPs/instructions

Cited by Anney Lin, Nathan E Hellman

14 Apr 2025
21 CFR 211.84(d)(1)

Identity Testing of Each Component

Cited by Anney Lin, Nathan E Hellman

Inspected site

CCColumbia Cosmetics Manufacturing, Inc.San Leandro, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(f)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere